• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SD filed by Bio-Techne Corp

    5/30/25 4:30:27 PM ET
    $TECH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $TECH alert in real time by email
    SD 1 tech-20250530xsd.htm SD

    ​

    ​

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549


    FORM SD


    SPECIALIZED DISCLOSURE REPORT


    BIO-TECHNE CORPORATION

    (Exact name of registrant as specified in its charter)


    ​

    Minnesota

    000-17272

    41-1427402

    (State or other jurisdiction of
    incorporation or organization)

    (Commission
    File Number)

    (I.R.S. Employer
    Identification No.)

    ​

    614 McKinley Place NE Minneapolis, MN

    55413

    (Address of principal executive offices)

    (Zip Code)

    ​

    Shane V. Bohnen (612) 851-4841

    (Name and telephone number, including area code, of the person to contact in connection with this report)


    Check the appropriate box to indicate the rule pursuant to which this form is being filed, and provide the period to which the information in this form applies:

    ​

    ☒

    Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2024.

    ​

    ​

    ​

    1


    ​

    SECTION 1 – CONFLICT MINERALS DISCLOSURE

    Item 1.01 Conflict Minerals Disclosure and Report

    Most of the products Bio-Techne manufactures or contracts to manufacture do not contain conflict minerals. However, under our ProteinSimple brand included in our Analytical Solutions Division, we sell instruments, some of which include tin, tungsten, tantalum and/or gold (“3TG”). We also sell two other small groups of reagent products, one under our Novus Biologicals and R&D Systems brands that contains 3TG. These product lines collectively are the subject of this Report.

    ​

    Conflict Minerals Disclosure

    A copy of Bio-Techne Corporation’s Conflict Minerals Report is provided as Exhibit 1.01 hereto and is publicly available at www.bio-techne.com .

    Item 1.02 Exhibit

    As specified in Section 2, Item 2.01 of this Form SD, the Company is hereby filing its Conflict Minerals Report as Exhibit 1.01 to this Form SD.

    SECTION 2 – EXHIBITS

    Item 2.01 Exhibits

    Exhibit 1.01 – Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form.

    ​

    2


    ​

    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    Date: May 30, 2025

    By:

    /s/ Shane V. Bohnen

    ​

    Name:

    Shane V. Bohnen

    ​

    Title:

    Senior Vice President, General Counsel and Secretary

    ​

    3


    Get the next $TECH alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TECH

    DatePrice TargetRatingAnalyst
    8/21/2025$70.00Neutral → Buy
    Citigroup
    7/22/2025$65.00Overweight
    Stephens
    7/9/2025$65.00Buy
    TD Cowen
    5/30/2025$59.00Overweight
    Wells Fargo
    4/9/2025Overweight → Sector Weight
    KeyBanc Capital Markets
    3/18/2025$75.00Outperform
    Evercore ISI
    2/19/2025$88.00 → $68.00Outperform → Neutral
    Robert W. Baird
    5/22/2024$85.00Buy → Neutral
    Citigroup
    More analyst ratings

    $TECH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CFO Hippel James converted options into 4,010 shares and covered exercise/tax liability with 1,926 shares, increasing direct ownership by 2% to 129,883 units (SEC Form 4)

    4 - BIO-TECHNE Corp (0000842023) (Issuer)

    8/19/25 5:38:01 PM ET
    $TECH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Herr Amy E. converted options into 279 shares and covered exercise/tax liability with 101 shares (SEC Form 4)

    4 - BIO-TECHNE Corp (0000842023) (Issuer)

    8/19/25 5:29:27 PM ET
    $TECH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Executive Officer Kelderman Kim converted options into 8,543 shares and covered exercise/tax liability with 4,305 shares, increasing direct ownership by 9% to 50,968 units (SEC Form 4)

    4 - BIO-TECHNE Corp (0000842023) (Issuer)

    8/19/25 5:28:49 PM ET
    $TECH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TECH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Bio-Techne upgraded by Citigroup with a new price target

    Citigroup upgraded Bio-Techne from Neutral to Buy and set a new price target of $70.00

    8/21/25 8:10:31 AM ET
    $TECH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Stephens resumed coverage on Bio-Techne with a new price target

    Stephens resumed coverage of Bio-Techne with a rating of Overweight and set a new price target of $65.00

    7/22/25 7:51:31 AM ET
    $TECH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    TD Cowen initiated coverage on Bio-Techne with a new price target

    TD Cowen initiated coverage of Bio-Techne with a rating of Buy and set a new price target of $65.00

    7/9/25 8:26:14 AM ET
    $TECH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TECH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ScaleReady Announces Award of a G-Rex® Grant to the Gates Institute's Translational Sciences Laboratory

    ST. PAUL, Minn., Aug. 14, 2025 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation and CellReady, today announced that the Translational Sciences Laboratory at Gates Institute, a leading contract development and manufacturing organization (CDMO) based at the University of Colorado Anschutz Medical Campus, has been awarded a $300,000 G-Rex® Grant to develop a modular G-Rex centric CAR T-cell manufacturing platform. "We are grateful for the generous G-Rex Grant funding, which will support the development of efficient and adaptable manufacturing approaches for our cell and gene therapy (CGT) programs," said Dr. Veena Krishnamoorthy, Director of Tr

    8/14/25 7:00:00 AM ET
    $TECH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Bio-Techne Releases Fourth Quarter Fiscal 2025 Results

    MINNEAPOLIS, Aug. 6, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the fourth quarter ending June 30, 2025. Fourth Quarter FY2025 Highlights Fourth quarter organic revenue increased by 3% (4% reported) to $317.0 million. Full year organic revenue increased 5% (5% reported) to $1.2 billion.GAAP earnings per share (EPS) was $ (0.11) versus $0.25 one year ago. Delivered adjusted EPS of $0.53 compared to $0.49 one year ago. Full year GAAP EPS was $0.46 versus $1.05 one year ago. Full year adjusted EPS was $1.92 versus $1.77 one year ago.Strong performance in our proteomic analytic and cell therapy growth pillars drove 4% organic growth (6% rep

    8/6/25 6:30:00 AM ET
    $TECH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BIO-TECHNE DECLARES DIVIDEND

    MINNEAPOLIS, Aug. 6, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended June 30, 2025. The quarterly dividend will be payable August 29, 2025, to all common shareholders of record on August 18, 2025. Future cash dividends will be considered by the Board of Directors on a quarterly basis. Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific

    8/6/25 6:30:00 AM ET
    $TECH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TECH
    Leadership Updates

    Live Leadership Updates

    View All

    Bio-Techne Appoints Dr. Amy E. Herr to Board of Directors

    MINNEAPOLIS, Feb. 4, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced the appointment of Amy E. Herr, Ph.D. to serve as an independent director on the Company's Board of Directors beginning on February 1, 2025. Dr. Herr will serve on the Science & Technology Committee of the Board of Directors. Dr. Herr is a Chancellor's Professor of Bioengineering at the University of California, Berkeley. Dr. Herr also currently serves as the Vice President of the Chan Zuckerberg Biohub Network, a group of nonprofit research institutes established to create tools required to understand the mysteries of the cell to ultimately cure, prevent, and manage human disease. Since joining th

    2/4/25 7:00:00 AM ET
    $TECH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BIO-TECHNE APPOINTS DR. JUDITH KLIMOVSKY TO BOARD OF DIRECTORS

    MINNEAPOLIS, April 30, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced the appointment of Dr. Judith Klimovsky to serve as an independent director on the Company's Board of Directors, April 24, 2024. Dr. Klimovsky will serve as a member of the Science and Technology Committee. Following the appointment, the board of Bio-Techne will be temporarily comprised of eleven directors, ten of whom are independent. Dr. Klimovsky is currently the Executive Vice President and Chief Development Officer at Genmab, an international biotechnology company specialized in the creation and development of antibody therapeutics. Before joining Genmab in 2017, Dr. Klimovsky held various s

    4/30/24 7:00:00 AM ET
    $TECH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BIO-TECHNE ANNOUNCES APPOINTMENT OF MATTHEW F. McMANUS AS PRESIDENT, DIAGNOSTICS AND GENOMICS SEGMENT

    MINNEAPOLIS, Jan. 5, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced Matthew F. McManus has been appointed President, Diagnostics and Genomics Segment, effective January 8, 2024. Dr. McManus succeeds Kim Kelderman, who will become Bio-Techne's Chief Executive Officer effective February 1, 2024. Dr. McManus has over two decades of experience as a senior life sciences leader, most recently serving as Executive Vice President and Chief Operating Officer for Azenta, where he was responsible for Life Sciences Products, Services, and all commercial operations of the business. Previously, Dr. McManus was Senior Vice President and General Manager of Bio-Techne's Molecular D

    1/5/24 7:00:00 AM ET
    $TECH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TECH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Bio-Techne Corp

    SC 13G - BIO-TECHNE Corp (0000842023) (Subject)

    11/14/24 1:22:36 PM ET
    $TECH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Bio-Techne Corp (Amendment)

    SC 13G/A - BIO-TECHNE Corp (0000842023) (Subject)

    2/13/24 5:00:46 PM ET
    $TECH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Bio-Techne Corp (Amendment)

    SC 13G/A - BIO-TECHNE Corp (0000842023) (Subject)

    2/9/23 11:12:40 AM ET
    $TECH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TECH
    Financials

    Live finance-specific insights

    View All

    Bio-Techne Releases Fourth Quarter Fiscal 2025 Results

    MINNEAPOLIS, Aug. 6, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the fourth quarter ending June 30, 2025. Fourth Quarter FY2025 Highlights Fourth quarter organic revenue increased by 3% (4% reported) to $317.0 million. Full year organic revenue increased 5% (5% reported) to $1.2 billion.GAAP earnings per share (EPS) was $ (0.11) versus $0.25 one year ago. Delivered adjusted EPS of $0.53 compared to $0.49 one year ago. Full year GAAP EPS was $0.46 versus $1.05 one year ago. Full year adjusted EPS was $1.92 versus $1.77 one year ago.Strong performance in our proteomic analytic and cell therapy growth pillars drove 4% organic growth (6% rep

    8/6/25 6:30:00 AM ET
    $TECH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BIO-TECHNE DECLARES DIVIDEND

    MINNEAPOLIS, Aug. 6, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended June 30, 2025. The quarterly dividend will be payable August 29, 2025, to all common shareholders of record on August 18, 2025. Future cash dividends will be considered by the Board of Directors on a quarterly basis. Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific

    8/6/25 6:30:00 AM ET
    $TECH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Bio-Techne to Host Conference Call on August 6, 2025, to Announce Fourth Quarter and Fiscal 2025 Financial Results

    MINNEAPOLIS, July 17, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that management will host a conference call and webcast on Wednesday, August 6, 2025, at 8:00 a.m. CDT to review its fourth quarter and fiscal 2025 financial results. Access to the discussion may be obtained as follows: Time: 8:00 a.m. CDT Date: August 6, 2025 Dial-in: 1-800-274-8461 or 1-203-518-9814 (for international callers) Conference ID: TECHQ4 Webcast: https://investors.bio-techne.com/ir-calendar A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-844-512-2921 or 1-412-317-6671 (for international callers) and referen

    7/17/25 7:00:00 AM ET
    $TECH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TECH
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Bio-Techne Corp

    SCHEDULE 13G/A - BIO-TECHNE Corp (0000842023) (Subject)

    8/14/25 1:07:20 PM ET
    $TECH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Bio-Techne Corp filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

    8-K - BIO-TECHNE Corp (0000842023) (Filer)

    8/6/25 6:30:25 AM ET
    $TECH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 144 filed by Bio-Techne Corp

    144 - BIO-TECHNE Corp (0000842023) (Subject)

    6/9/25 4:19:36 PM ET
    $TECH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care